U.S. FDA GRANTS FULL APPROVAL OF VITRAKVI® (LAROTRECTINIB) FOR ADULT AND PEDIATRIC PATIENTS WITH NTRK GENE FUSION-POSITIVE SOLID TUMORS

Reuters · 04/10 12:40

Please log in to view news